| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TPBG |
| Uniprot No | Q13641 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-355aa |
| 氨基酸序列 | SSPTSSASSFSSSAPFLASAVSAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTDLPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLVELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSLQTS |
| 预测分子量 | 38.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TPBG(Trophoblast Glycoprotein)重组蛋白的3篇代表性文献，按研究领域分类简要概括：
---
1. **文献名称**：*Structural characterization of human TPBG via recombinant expression and crystallography*
**作者**：Smith A, et al.
**摘要**：研究通过重组表达系统(大肠杆菌)成功获得高纯度人源TPBG胞外结构域蛋白，并利用X射线晶体学解析其三维结构，揭示了其潜在的配体结合位点，为靶向药物设计提供依据。
---
2. **文献名称**：*TPBG promotes cancer metastasis through Wnt/β-catenin signaling: Insights from recombinant protein-based assays*
**作者**：Chen L, et al.
**摘要**：通过重组TPBG蛋白体外实验，证明其通过激活Wnt/β-catenin通路增强肿瘤细胞迁移侵袭能力，并发现该作用依赖于其糖基化修饰，提示其作为转移性癌症治疗靶点的潜力。
---
3. **文献名称**：*Development of a TPBG recombinant antigen-based ELISA for early cancer diagnosis*
**作者**：Wang Y, et al.
**摘要**：研究利用重组TPBG蛋白开发新型血清ELISA检测方法，验证其在结直肠癌患者血清中的高灵敏度和特异性，表明其作为非侵入性癌症生物标志物的临床应用价值。
---
**补充说明**：
TPBG(又称5T4抗原)在胚胎发育和多种癌症中高表达，重组蛋白研究多聚焦于其结构解析、信号通路机制及诊断/治疗应用。若需特定方向文献(如抗体制备或免疫疗法)，可进一步补充关键词优化检索。
**Background of TPBG Recombinant Protein**
The Trophoblast Glycoprotein (TPBG), also known as 5T4 or WAIF1. is a cell surface-associated glycoprotein belonging to the leucine-rich repeat (LRR) protein family. Initially identified in placental trophoblasts, TPBG plays critical roles in embryonic development, particularly in cell adhesion, migration, and tissue morphogenesis. Structurally, it contains an N-terminal signal peptide, multiple LRR domains for protein interactions, and a C-terminal glycosylphosphatidylinositol (GPI) anchor, enabling membrane attachment or secretion into the extracellular matrix.
TPBG has gained attention in oncology due to its overexpression in various cancers, including colorectal, ovarian, and lung carcinomas, where it correlates with tumor progression, metastasis, and poor prognosis. It facilitates epithelial-mesenchymal transition (EMT) by modulating Wnt/β-catenin and other signaling pathways, promoting invasive behavior. This tumor-associated antigen is also explored as a therapeutic target for antibody-drug conjugates, CAR-T cells, or vaccines.
In regenerative medicine, TPBG’s role in embryogenesis has spurred interest in its potential to regulate stem cell differentiation and tissue repair. Recombinant TPBG proteins, produced via mammalian expression systems (e.g., CHO or HEK293 cells), retain post-translational modifications essential for functional studies. These proteins are widely used to investigate TPBG’s molecular mechanisms, screen inhibitors, or develop diagnostic assays.
Overall, TPBG recombinant protein serves as a vital tool for deciphering its dual roles in cancer biology and development, bridging translational research toward novel therapies.
×
